Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
PLOS Digital Health|May 26, 2026
Moving beyond the benchmarks: Five foundational principles for meaningful AI evaluation in healthcareCatherine G Bielick, Aya Awwad, Jacob Ellen, et al.JAMA Network Open|October 15, 2025
Implications of a New Obesity Definition Among the All of Us CohortLindsay T Fourman, Aya Awwad, Alba Gutiérrez-Sacristán, et al.BMC Nephrology|May 30, 2024
Comparative CKD risk prediction using homocitrulline and carbamylated albumin: two circulating markers of protein carbamylationAya Awwad, Eugene P Rhee, Morgan Grams, et al.AIDS (London, England)|June 26, 2026
Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVEAya Awwad, Upasana Das Adhikari, Tricia H Burdo, et al.Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.Circulation. Heart Failure|December 29, 2025
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S Bloomfield, Maya Watanabe, Sara McCallum, et al.AIDS (London, England)|May 27, 2025
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trialChristopher deFilippi, Aya Awwad, Gerald S Bloomfield, et al.The Lancet. HIV|April 3, 2025
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trialMarissa R Diggs, Triin Umbleja, Sara McCallum, et al.The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.Pageof 2